Abstract: Background. Little is known about real-world outcomes for new interferon-free treatment for hepatitis C virus (HCV) among underserved and diverse communities. Objective. To identify predictors of treatment prescription and evaluate outcomes as measured by sustained virologic response (SVR) with HCV RNA testing three months after therapy completion. Design. Retrospective cohort at a safety-net health care system. Participants. Patients with (1) at least one clinical visit between December 6, 2013, and December 31 st 2014; and (2) at least three months follow-up. Key results. Predominantly non-White cohort (61%). Of 1,284 HCV-infected patients 121 prescribed sofosbuvir-based therapy. Severe liver fibrosis (OR 1.66, 95% CI 1.05, 2.64) independently associated with treatment prescription. In those with evaluable HCV RNA, SVR was 99%. Conclusion. Cure rates similar to clinical trial data can be achieved in diverse underserved communities.
drugs have recorded high rates of sustained virologic response (SVR) in randomized, controlled clinical trials, but data about real-world outcomes are only now emerging.
Given the growing enthusiasm for the goal of eradicating HCV in the United States, 4 it is particularly important to understand treatment effectiveness within urban, safety-net health care systems, where HCV prevalence is high, new infections are being transmitted, the patient population is ethnically diverse, and high rates of both drug use and poverty complicate therapy. 5, 6 Until now, HCV treatment initiation and SVR have been rare events among urban patients. In a study including 293 HCV-infected patients at an urban Ohio county hospital, 28% (83) were treated and only 13% (11) of those treated achieved SVR. 7 The availability of interferon-free treatment options will likely lead to more treatment initiations and SVR at safety-net centers, but there are currently no data available to test that hypothesis. Data from national registries or integrated health systems provide information from large populations of treated patients, [8] [9] [10] [11] but they are not generalizable to safety-net centers caring for uninsured or underinsured populations and individuals who are disproportionally affected by HCV.
We therefore sought to evaluate HCV treatment outcome at a large, urban safety-net health care system during the new interferon free era. The objectives of the study were (1) to identify predictors of treatment prescription and (2) to evaluate outcomes as measured by SVR with HCV RNA testing three months after therapy completion. We also sought to describe the demographic characteristics of HCV-infected patients prescribed sofosbuvir-based therapy, and to compare individuals prescribed sofosbuvir to HCV-infected patients who were followed during the same time period, but were not started on treatment. We hypothesized that during the early interferon-free era HCV-infected patients with more severe liver fibrosis would be prioritized for treatment.
Methods
Overview. We used the electronic medical record (EMR) at Boston Medical Center (BMC) to create a retrospective cohort of patients diagnosed with HCV between January 1 st , 2004, and December 31 st , 2014. We included patients with reactive HCV antibody or individuals with negative antibody, but with documented detectable HCV viral load at least six months after serology testing. The latter cases were likely patients of acute HCV infection who were identified prior to seroconversion.
Site. Boston Medical Center is a non-profit academic medical center. It is the largest safety-net hospital in New England and 70% of the patients at BMC are from underserved groups including ethnic/racial minorities, immigrants and the elderly. 12 Safety-net hospitals provide care to low-income as well as uninsured or underinsured populations. Boston Medical Center is the only academic medical center in Massachusetts also classified as a Disproportionate Share Hospital (DSH). As a DSH, BMC serves a large proportion of low-income patients and receives Centers for Medicaid and Medicare Services payments to cover the care provided to uninsured patients. In 2013, the hospital's overall payer mixed was 23% commercial insurance, 27% Medicare and other federal programs and 49% state programs.
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Primary outcome. Our primary outcome was sofosbuvir prescription during the first year of interferon-free treatment availability. The FDA approved sofosbuvir on Independent variables. We included the following covariates in the analysis: age at baseline, gender, race/ethnicity, insurance, HIV status, birthplace, number of follow-up visits during the study period (dichotomized at the median), and liver fibrosis staging as measured by fibrosis 4 (FIB 4)-index. FIB-4 is a non-invasive measurement of hepatic fibrosis calculated using the following formula:
. FIB-4 index of 3.25 or greater is an indication of severe fibrosis.
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Statistical analysis. We used descriptive statistics to estimate the proportion of patients who were prescribed sofosbuvir-based therapy and the proportion of individuals with SVR. We computed as-treated SVR, determined using the proportion of patients who had available RNA testing three months after treatment completion. Additionally, we estimated and tested a multivariate logistic regression including variables significant in univariate analysis and potential confounders. We estimated odds ratios with 95% confidence intervals and all p-value significance levels were two-sided. Statistical analyses were performed with STATA 12 (STATA, College Station, TX).
Regulatory approvals. The Boston University Medical Center Institutional Review Board approved this study. (Figure 1 ). The mean age was 47 years and the cohort was predominantly male (64%), and non-White (43% Black, 10% Latino, 2% Asian, 6% other). More than half (56%) had public insurance including Medicaid and Medicare, and 14% were covered by Health Safety Net, the Massachusetts state sponsored program covering health services for uninsured or underinsured Massachusetts residents. Eleven percent of the cohort was HIV-coinfected, but 524 (41%) had no record of HIV testing. A majority (755, 59%) had a history of substance use recorded as an International Classification of Diseases (ICD)-9 code for either heroin, alcohol, or any other illicit drug use. Median follow-up time was nine months (range 3-13 months). Eighteen percent of the cohort had a calculated FIB-4 index suggestive of severe liver fibrosis, including 27% of individuals who initiated sofosbuvir-based therapy and 17% of those who were not treated during the time period of interest (p-value <.01) ( Treatment outcomes. In an as-treated analysis, we identified 75 patients who had HCV RNA testing available three months after treatment. Of those, 74 (99%) achieved SVR (Figure 2) . Of the 31 patients who did not have any HCV RNA testing, 53% had no visits with either a gastroenterology or an infectious diseases subspecialist after the prescription had been written. Of the 75 HCV-infected patients with available HCV RNA testing at three months, 61 (81%) were treatment-naïve. Sustained virologic response rates were 98% and 100% for treatment-naïve and treatment-experienced individuals, respectively.
Results

Discussion
Our findings provide much needed information about interferon-free treatment outcomes at an urban, safety-net hospital system. Similar to our prior studies and those of others, we found a high HCV detection rate of 15%. 5, 6 While most infected patients had not yet been treated by the end of the first year of sofosbuvir availability, it is encouraging that over 10% of known cases were treated within 12 months of sofosbuvir approval, especially when this treatment initiation rate is compared to the interferon era.
Sofosbuvir-based therapy was associated with more advanced liver fibrosis. It is possible that during the early interferon-free treatment era, providers and payers are focusing efforts on HCV-infected patients with more severe disease who are at high-risk for progression to decompensated cirrhosis or other HCV complications. This practice is consistent with The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines identifying individuals with advanced disease as a priority group, 16 and also reflects common restrictions on access to therapy. 17 Less expected was the high proportion of patients who received HCV therapy without a documented HIV serology in the medical record. This finding is surprising, given that HIV and HCV share a common mode of transmission and that guidance clearly recommends that HCV-infected patients should also be tested for HIV co-infection. 16 It is possible that individuals might have been tested for HIV elsewhere and that results were not available in our system. Importantly, we found cure rates comparable to clinical trials, demonstrating that new HCV therapies are effective, even in a real-world setting characterized by a diverse patient population and a high prevalence of substance use. Additionally, cure rates were high in both treatment-naïve and treatment-experienced individuals. Our findings are similar to those reported from large national registries and from the Veterans Administration, and extend those findings to a new, high-priority treatment setting. [8] [9] [10] 18, 19 These data should inform ongoing discussions about the appropriateness of cost-control strategies that limit treatment access only to specific centers of excellence, as well as debate about the ability to treat HCV among recent and active drug users. 20 Prior studies have focused on treatment initiation during the interferon era. For example, in a retrospective case series of 327 patients referred for HCV evaluation at an urban teaching, county hospital in Ohio, 28% were treated and only 13% had SVR. 7 In another urban cohort in Baltimore, including 597 HCV-infected individuals, only 26 initiated treatment and only five reached SVR. 21 More recent data presented at national and international conferences revealed real-world outcomes of HCV treatment during the interferon-free era; however, the patient population is not representative of the diverse low-income population disproportionally affected by HCV. [8] [9] [10] 19 One of those studies involved the Veteran Affairs (VA) population-a predominantly male population with access to care. The VA study included approximately 4,000 HCVinfected patients and reported lower SVR rates than in clinical trials. Sustained virologic response rates were between 70-80% depending on the genotype and the regimen administered. Another study, the HCV-TARGET International registry, included approximately 2000 HCV-infected patients and reported SVR rates similar to clinical trials data. For example, reported SVR rates with sofosbuvir/ledipasvir regimen were approximately 95% after three months of treatment, similar to outcomes in clinical trials. In this particular study, however, only 2% of the participants were HIV-infected, and 12% were Black, differing greatly from the demographic profile of the current real world study.
There are limitations to this study, including a single site and a retrospective study design that might limit generalizability. We were not able to control for other comorbidities that could influence treatment initiation and outcomes because of incomplete ICD-9 codes for history of substance use. We were also not able to assess if substance use was in remission or active. Another limitation is that we did not have genotype test results on most of the individuals included in the study.
In conclusion, our study provides important information on treatment initiation and completion during the early interferon-free era. In our study, HCV-infected patients with severe liver disease had a high chance of being prescribed sofosbuvir-based treatment. We also demonstrate that SVR rates similar to clinical trials results can be achieved in safety-net hospitals with a high proportion of Medicaid and underinsured patients. These findings suggest that HCV eradication might be possible during the interferon-free era, but measures are necessary to ensure access to treatment at safety-net hospitals. Interferon-free therapy has transformed the landscape of HCV management, but continued efforts are necessary to ensure that treatment reaches its maximum potential in high prevalence areas. Future studies are needed on long-term outcomes of sofosbuvir-based treatment for HCV in safety-net hospitals and to determine why some individuals prescribed treatment do not initiate it during the new HCV treatment era.
